Other molecular markers have been postulated for platinum-based chemotherapy in NSCLC, such as excision repair cross-complementation group 1 (ERCC1) protein expression in tumor tissue [13] and ERCC1 germline polymorphisms [14]. This evidence concerns the gene ERCC1 and neoplasm.